Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Equal-Weight rating on Exelixis (NASDAQ:EXEL) while raising the price target from $26 to $28.
October 11, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Exelixis and increased the price target from $26 to $28, indicating a positive outlook.
The increase in price target from $26 to $28 by Morgan Stanley suggests a positive outlook for Exelixis, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100